AIM ImmunoTech Inc. (AIM)
Healthcare · Biotechnology · AMEX · US
$0.18+0.00%Close
SELLCRISIS · day 28
$0.18+0.00%
Key stats
Short interest · FINRA settlement 2026-09-15
- Market cap
- $612,637
- Beta
- 1.27
- P/E (TTM)
- -0.05
- Short % float
- 99.54%
- Days to cover
- 1.0
- SI change
- +382.9%
- 1W
- -5.26%
- 1M
- -21.74%
- vs SPY 1W
- -6.82%
- vs SPY 1M
- -23.50%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
AIM ImmunoTech's Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays
AIM ImmunoTech Highlights Recent Media Coverage of Ampligen's® Broad-Spectrum Antiviral and Biodefense Potential
AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data
Ionic Rare Earths targets AIM listing as Belfast magnet recycling strategy gathers pace
AIM ImmunoTech Discusses Ampligen®'s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video
Ondine Biomedical pauses trading to raise fresh investment after positive phase III result
1947 Oil & Gas starts AIM trading after £50m fundraising and Gulf acquisition
1947 Oil & Gas makes AIM debut with ambitions to grow production sharply in coming years
Digitalbox eyes creator-led growth as it rides out Meta disruption
AIM ImmunoTech Highlights Ampligen's Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines' Daraxonrasib
Shore Capital cheers Coiled Therapeutics dosing progress
Coiled Therapeutics fills two cohorts as reworked cancer drug advances
Kefi confirms staff safe after fatal Tulu Kapi attack as local investors step up
Sintana Energy advances deal to acquire KON-16 in Angola
AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video
Ondine Biomedical strikes deal with Mexico's largest private hospital network
AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041
AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039
Metals One partner rejects claim that Barbrook mine deal has failed
AIM ImmunoTech Participates in the Virtual Investor ‘Why Now' On-Demand Conference
